HANGZHOU TIANMUSHAN PHARMACEUTICAL ENTERPRISE CO.,LTD

News Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

Equities

600671

CNE000000BF3

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-07-04 pm EDT			5-day change	1st Jan Change
7.65 ^CNY	+1.86%		+3.24%	-34.39%

Jul. 04	Tianmushan Pharmaceutical's Amoxicillin Clavulanate Potassium Tablets Pass Chinese Drug Regulator's Consistency Evaluation	MT
May. 24	Tianmushan Pharmaceutical Enterprise to Revamp Production Line for 100 Million Yuan	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Tianmushan Pharmaceutical's Amoxicillin Clavulanate Potassium Tablets Pass Chinese Drug Regulator's Consistency Evaluation	Jul. 04	MT
Tianmushan Pharmaceutical Enterprise to Revamp Production Line for 100 Million Yuan	May. 24	MT
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
Qingdao Yuanjia Medical Treatment Technology proposal of Adding Sheng Xiaofan to the Company's Eleventh Board of Directors to Hangzhou TianMuShan Pharmaceutical Enterprise was approved.	23-10-30	CI
On October 19, 2023 Qingdao Yuanjia Medical Treatment Technology propose of Adding Sheng Xiaofan to the Company's Eleventh Board of Directors to Hangzhou TianMuShan Pharmaceutical Enterprise.	23-10-19	CI
TianMuShan Pharma Elects Chairman	23-10-16	MT
Qingdao Yuanjia Medical Treatment Technology Co., Ltd. completed the acquisition of 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd.	23-10-12	CI
Qingdao Huilong Huaze Investment Co., Ltd. completed the acquisition of 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd.	23-10-12	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-10	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
TianMuShan Pharmaceutical CFO Steps Down	23-08-21	MT
Qingdao Huilong Huaze Investment Co., Ltd. agreed to acquire 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY 90 million.	23-08-20	CI
Qingdao Yuanjia Medical Treatment Technology Co., Ltd. agreed to acquire 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY140 million.	23-08-20	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd announced that it expects to receive CNY 278.385575 million in funding from Qingdao Huilong Huaze Investment Co., Ltd.	23-08-17	CI
Yongxin Huarui Proposes Board and Supervisory Board Nominations for Hangzhou Tianmushan's Board	23-05-14	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Auditor Raises 'Going Concern' Doubt	23-04-24	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

Equities

600671

CNE000000BF3

Summary

Filters